Erschienen in:
07.06.2019 | Editorial
Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts’ consensus recommendations
verfasst von:
Felix Bongomin, Nelesh P. Govender, Arunaloke Chakrabarti, Florence Robert-Gangneux, David R. Boulware, Afia Zafar, Rita O. Oladele, Malcolm D. Richardson, Jean-Pierre Gangneux, Ana Alastruey-Izquierdo, Joel Bazira, Tom H. Boyles, Jahit Sarcarlal, Mathieu Nacher, Taminori Obayashi, William Worodria, Alessandro C. Pasqualotto, David B. Meya, Ben Cheng, Charlotte Sriruttan, Conrad Muzoora, Andrew Kambugu, Juan Luis Rodriguez Tudela, Alexander Jordan, Tom M. Chiller, David W. Denning
Erschienen in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Ausgabe 9/2019
Einloggen, um Zugang zu erhalten
Excerpt
An accurate, timely diagnosis is the cornerstone of good medical practice. For opportunistic fungal infections in AIDS and other invasive mycoses, this is dependent on the availability of and accessibility to the relevant diagnostic tests. A call for a model List of Essential In Vitro Diagnostics (EDL)—“listed tests that should be reasonably available for people who need them, whether in the form of point-of-care tests in physicians’ offices and pharmacies or as high-complexity tests in reference laboratories”—has been published [
1]. In addition to better medical practice, other potential benefits of an EDL include clarification of priorities for policy makers, setting common goals for laboratory testing, improved healthcare delivery and overall better patient outcomes [
1]. In the context of extensive antimicrobial resistance (AMR), a reduction in empiricism with more accurate diagnosis will play a key role in AMR control [
2]. …
